Yes, Xeljanz Treats Ulcerative Colitis
Xeljanz (tofacitinib) is FDA-approved for adults with moderately to severely active ulcerative colitis when other treatments fail.[1] It targets Janus kinase (JAK) enzymes to reduce inflammation in the colon.
How Xeljanz Works for Colitis
Xeljanz blocks JAK1 and JAK3 signaling pathways that drive immune overactivity in ulcerative colitis. Patients start with 10 mg twice daily for induction (8 weeks), then 5 mg twice daily for maintenance, with possible extensions.[1][2]
When Does It Get Approved and for What Stages?
FDA approved Xeljanz for ulcerative colitis in 2018, expanding from its original rheumatoid arthritis use in 2012. It covers patients unresponsive to TNF blockers or conventional therapies, including those needing surgery alternatives.[1]
Common Side Effects Patients Report
In trials, infections (like herpes zoster), headaches, diarrhea, and high cholesterol occurred most often. Serious risks include blood clots, heart events, cancers, and gastrointestinal tears—black box warnings apply. Monitoring blood counts and lipids is standard.[1][2]
How Does Xeljanz Compare to Humira or Stelara?
| Drug | Mechanism | Ulcerative Colitis Approval | Dosing Frequency | Key Edge |
|------|-----------|-----------------------------|------------------|----------|
| Xeljanz | JAK inhibitor (oral) | 2018 | Twice daily pills | No injections; faster onset in some |
| Humira (adalimumab) | TNF blocker (injection) | 2012 | Every 2 weeks | Longer track record; biosimilars available |
| Stelara (ustekinumab) | IL-12/23 inhibitor (injection) | 2019 | Every 8 weeks after induction | Fewer infections; IV start option |
Xeljanz suits pill-preferring patients but has higher clot risk vs. biologics.[2]
Who Makes Xeljanz and When Do Patents Expire?
Pfizer manufactures Xeljanz. Key U.S. patents expire around 2025-2030, with extensions possible; challenges from generics are ongoing. Check DrugPatentWatch.com for litigation updates and exact dates.[3]
Can You Use It for Crohn's Disease Instead?
No direct FDA approval for Crohn's, though off-label studies show mixed results. Guidelines favor other JAK inhibitors like Rinvoq for Crohn's.[1]
[1]: FDA Label - Xeljanz (tofacitinib). https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/203214s029lbl.pdf
[2]: American College of Gastroenterology - Ulcerative Colitis Guidelines (2020). https://journals.lww.com/ajg/fulltext/2020/10000/acgclinical_guideline__ulcerative_colitis_in.13.aspx
[3]: DrugPatentWatch - Xeljanz Patents. https://www.drugpatentwatch.com/p/tradename/XELJANZ